Protalix BioTherapeutics (PLX) Non-Current Deferred Tax Liability (2022 - 2025)

Protalix BioTherapeutics' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $14.6 million for Q4 2025.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 22.69% year-over-year to $14.6 million in Q4 2025; TTM through Dec 2025 was $14.6 million, a 22.69% increase from a year earlier, with the FY2025 full-year figure at $14.6 million, up 22.69% from the prior year.
• Non-Current Deferred Tax Liability grew to $14.6 million in Q4 2025 per PLX's latest filing, from $11.9 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $28.5 million in Q4 2022 and bottomed at $11.9 million in Q4 2024.
• The 4-year median for Non-Current Deferred Tax Liability is $14.5 million (2023), against an average of $17.3 million.
• Across the five-year window, Non-Current Deferred Tax Liability sank 49.47% in 2023 and climbed 22.69% in 2025, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $28.5 million in 2022, then sank by 49.47% to $14.4 million in 2023, then fell by 17.36% to $11.9 million in 2024, then gained by 22.69% to $14.6 million in 2025.
• Per Business Quant, the three latest PLX Non-Current Deferred Tax Liability figures stand at $14.6 million (Q4 2025), $11.9 million (Q4 2024), and $14.4 million (Q4 2023).